{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:36:20Z","timestamp":1792820180599,"version":"4.5.0"},"reference-count":100,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"the Italian Ministry of Health"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2023,12,2]]},"DOI":"10.1080\/14712598.2023.2274912","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T13:40:34Z","timestamp":1698154834000},"page":"1227-1237","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Antibody based therapeutics for autoimmune hemolytic anemia"],"prefix":"10.1080","volume":"23","author":[{"given":"Francesca","family":"Cavallaro","sequence":"first","affiliation":[{"name":"Hematology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma","family":"Barcellini","sequence":"additional","affiliation":[{"name":"Hematology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fattizzo","sequence":"additional","affiliation":[{"name":"Hematology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,11]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2033982"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2023.2216930"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003808"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583021"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25212"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13469"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100648"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0308-2261(21)00631-7"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.11.014"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2019.102388"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221097780"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2033982"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003809"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-196329"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024190"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9181698"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279812"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014955"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25020"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.216804"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.435.435"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.010"},{"issue":"11","key":"e_1_3_4_26_1","first-page":"1006","article-title":"Rituximab for refractory childhood autoimmune hemolytic anemia","volume":"4","author":"Motto DG","year":"2002","unstructured":"Motto DG, Williams JA, Boxer LA. Rituximab for refractory childhood autoimmune hemolytic anemia. Isr Med Assoc J. 2002 Nov;4(11):1006\u20131008.","journal-title":"Isr Med Assoc J"},{"issue":"9","key":"e_1_3_4_27_1","first-page":"1273","article-title":"Rituximab in the treatment of refractory autoimmune cytopenias in adults","volume":"90","author":"Narat S","year":"2005","unstructured":"Narat S, Gandla J, Hoffbrand AV, et al. Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica. 2005 Sep;90(9):1273\u20131274.","journal-title":"Haematologica"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21341"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12541"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12486"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24570"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2019.06.024"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3597"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500286481"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-288647"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-778175"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005674"},{"issue":"2","key":"e_1_3_4_38_1","first-page":"189","article-title":"B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia","volume":"87","author":"Zaja F","year":"2002","unstructured":"Zaja F, Iacona I, Masolini P, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica. 2002 Feb;87(2):189\u2013195. Erratum in: Haematologica 2002 Mar;87(3):336.","journal-title":"Haematologica"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3547"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2009.02126.x"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-010-0997-y"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12199"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14627"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-020-00163-5"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.9.3490"},{"key":"#cr-split#-e_1_3_4_46_1.1","unstructured":"A study of efficacy and safety of ianalumab in Previously treated patients with warm autoimmune hemolytic anemia (VAYHIA). ClinicalTrials.Gov Identifier: NCT05648968. [Updated 2023 May 25"},{"key":"#cr-split#-e_1_3_4_46_1.2","unstructured":"cited 2023 Jul 5]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05648968"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-015-1851-8"},{"key":"#cr-split#-e_1_3_4_48_1.1","unstructured":"An open-label study of povetacicept in subjects with autoimmune cytopenias (RUBY-4). ClinicalTrials.Gov Identifier: NCT05757570. [Updated 2023 Mar 7"},{"key":"#cr-split#-e_1_3_4_48_1.2","unstructured":"cited 2023 Jul 5]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05757570"},{"key":"#cr-split#-e_1_3_4_49_1.1","unstructured":"A study of obexelimab in patients with warm autoimmune hemolytic anemia (SApHiare). ClinicalTrials.Gov Identifier: NCT05786573. [Updated 2023 May 19"},{"key":"#cr-split#-e_1_3_4_49_1.2","unstructured":"cited 2023 Jul 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05786573"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012039"},{"key":"#cr-split#-e_1_3_4_51_1.1","unstructured":"Ibrutinib in steroid refractory autoimmune hemolytic anemia (ISRAEL). ClinicalTrials.Gov Identifier: NCT03827603. [Updated 2020 Jan 10"},{"key":"#cr-split#-e_1_3_4_51_1.2","unstructured":"cited 2023 Jul 5]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03827603"},{"key":"#cr-split#-e_1_3_4_52_1.1","unstructured":"Efficacy safety and pharmacokinetics of Rilzabrutinib in patients with warm autoimmune hemolytic anemia (wAIHA). ClinicalTrials.Gov Identifier: NCT05002777. Updated 2023 May 31"},{"key":"#cr-split#-e_1_3_4_52_1.2","unstructured":"cited 2023 Jul 5]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05002777"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26508"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211046428"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-835413"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018020883"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15539"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16171"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28010"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17655"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04063-w"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25932"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.649441"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40348-021-00114-y"},{"key":"#cr-split#-e_1_3_4_65_1.1","unstructured":"Safety pharmacokinetics and efficacy of subcutaneous isatuximab in adults with warm autoimmune hemolytic anemia (wAIHA). ClinicalTrials.Gov Identifier: NCT04661033. [Updated 2023 Mar 13"},{"key":"#cr-split#-e_1_3_4_65_1.2","unstructured":"cited 2023 Jul 5]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04661033"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1800-7"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.399"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3521-4"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04557-1"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-242937"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23791"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-226429"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3250"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26051"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-250774"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-556027"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-856930"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027760"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26409"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000972768.83270.db"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04948-y"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000561876.96057.48"},{"key":"#cr-split#-e_1_3_4_83_1.1","unstructured":"A study to evaluate the efficacy and safety of pegcetacoplan in patients with cold agglutinin disease (CAD). ClinicalTrials.Gov Identifier: NCT05096403. [Updated 2023 Jun 2"},{"key":"#cr-split#-e_1_3_4_83_1.2","unstructured":"cited 2023 Jul 5]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05096403"},{"key":"#cr-split#-e_1_3_4_84_1.1","unstructured":"Basket study to assess efficacy safety and PK of iptacopan (LNP023) in autoimmune benign hematological disorders. ClinicalTrials.Gov Identifier: NCT05086744. [Updated 2023 Jul 3"},{"key":"#cr-split#-e_1_3_4_84_1.2","unstructured":"cited 2023 Jul 5]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05086744"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9123859"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18011"},{"key":"#cr-split#-e_1_3_4_87_1.1","unstructured":"Study to assess the safety tolerability efficacy and PK of APL-2 in patients with warm type autoimmune hemolytic anemia (wAIHA) or cold agglutinin disease (CAD). ClinicalTrials.Gov Identifier: NCT03226678. [Updated 2023 Apr 3"},{"key":"#cr-split#-e_1_3_4_87_1.2","unstructured":"cited 2023 Jul 5]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03226678"},{"key":"#cr-split#-e_1_3_4_88_1.1","unstructured":"Safety tolerability pharmacokinetics and pharmacodynamics of ANX005 in participants with warm autoimmune hemolytic anemia (wAIHA). ClinicalTrials.Gov Identifier: NCT04691570. [Updated 2023 Mar 6"},{"key":"#cr-split#-e_1_3_4_88_1.2","unstructured":"cited 2023 Jul 5]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04691570"},{"key":"#cr-split#-e_1_3_4_89_1.1","unstructured":"A safety study of SYNT001 in participants with warm autoimmune hemolytic anemia (WAIHA). ClinicalTrials.Gov Identifier: NCT03075878. [Updated 2020 May 13"},{"key":"#cr-split#-e_1_3_4_89_1.2","unstructured":"cited 2023 Jul 5]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03075878"},{"key":"#cr-split#-e_1_3_4_90_1.1","unstructured":"To assess the efficacy and safety of RVT-1401 in the treatment of warm autoimmune hemolytic anemia (ASCEND-WAIHA). ClinicalTrials.Gov Identifier: NCT04253236. [Updated 2022 Jul 28"},{"key":"#cr-split#-e_1_3_4_90_1.2","unstructured":"cited 2023 Jul 5]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04253236"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2023.2274912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T19:31:40Z","timestamp":1727206300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2023.2274912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":100,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,2]]}},"alternative-id":["10.1080\/14712598.2023.2274912"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2023.2274912","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-07-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}